title: Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.
abstract: BACKGROUND
  Pre-clinical models that effectively recapitulate human disease are critical for expanding our knowledge of cancer biology and drug resistance mechanisms. For haematological malignancies, the non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse is one of the most successful models to study paediatric acute lymphoblastic leukaemia (ALL). However, for this model to be effective for studying engraftment and therapy responses at the whole genome level, careful molecular characterisation is essential.
  
  
  RESULTS
  Here, we sought to validate species-specific gene expression profiling in the high engraftment continuous ALL NOD/SCID xenograft. Using the human Affymetrix whole transcript platform we analysed transcriptional profiles from engrafted tissues without prior cell separation of mouse cells and found it to return highly reproducible profiles in xenografts from individual mice. The model was further tested with experimental mixtures of human and mouse cells, demonstrating that the presence of mouse cells does not significantly skew expression profiles when xenografts contain 90% or more human cells. In addition, we present a novel in silico and experimental masking approach to identify probes and transcript clusters susceptible to cross-species hybridisation.
  
  
  CONCLUSIONS
  We demonstrate species-specific transcriptional profiles can be obtained from xenografts when high levels of engraftment are achieved or with the application of transcript cluster masks. Importantly, this masking approach can be applied and adapted to other xenograft models where human tissue infiltration is lower. This model provides a powerful platform for identifying genes and pathways associated with ALL disease progression and response to therapy in vivo.
authors.affiliation: Division of Children's Leukaemia and Cancer Research, Telethon Institute for Child Health Research, Perth, Western Australia.
authors.forename: Amy L
authors.initials: AL
authors.lastname: Samuels
authors.forename: Violet K
authors.initials: VK
authors.lastname: Peeva
authors.forename: Rachael A
authors.initials: RA
authors.lastname: Papa
authors.forename: Marin J
authors.initials: MJ
authors.lastname: Firth
authors.forename: Richard W
authors.initials: RW
authors.lastname: Francis
authors.forename: Alex H
authors.initials: AH
authors.lastname: Beesley
authors.forename: Richard B
authors.initials: RB
authors.lastname: Lock
authors.forename: Ursula R
authors.initials: UR
authors.lastname: Kees
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000378:metabolism; D004195:Disease Models, Animal; D020869:Gene Expression Profiling; D006801:Humans; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics*; D013045:Species Specificity; D013154:Spleen / Q000378:metabolism
references.citation: Science. 1989 Dec 22;246(4937):1597-600
references.pmid: 2595371
references.citation: Endocr Relat Cancer. 2006 Jun;13(2):617-28
references.pmid: 16728587
references.citation: Clin Exp Metastasis. 2008;25(1):81-8
references.pmid: 17932773
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):161-5
references.pmid: 15688078
references.citation: Blood. 2002 Jun 1;99(11):4100-8
references.pmid: 12010813
references.citation: Curr Pharm Des. 2008;14(21):2023-39
references.pmid: 18691113
references.citation: Pediatr Hematol Oncol. 2000 Dec;17(8):635-50
references.pmid: 11127395
references.citation: Mol Cancer Res. 2005 Mar;3(3):119-29
references.pmid: 15798092
references.citation: Genome Biol. 2003;4(7):R46
references.pmid: 12844362
references.citation: Lancet. 2008 Mar 22;371(9617):1030-43
references.pmid: 18358930
references.citation: Blood. 2004 May 15;103(10):3905-14
references.pmid: 14764536
references.citation: Stat Appl Genet Mol Biol. 2004;3:Article3
references.pmid: 16646809
references.citation: Cancer Res. 2007 Jan 1;67(1):32-40
references.pmid: 17210681
references.citation: Br J Haematol. 2007 Sep;138(6):740-8
references.pmid: 17760805
references.citation: Nucleic Acids Res. 2005 Jul 19;33(13):e111
references.pmid: 16030348
references.citation: Br J Haematol. 2005 Nov;131(4):447-56
references.pmid: 16281934
references.citation: Eur J Cancer. 2004 Apr;40(6):837-44
references.pmid: 15120039
references.citation: Exp Hematol. 2001 Mar;29(3):322-9
references.pmid: 11274760
references.citation: Br J Cancer. 2009 Jun 16;100(12):1926-36
references.pmid: 19436302
references.citation: Br J Haematol. 2008 Mar;140(6):656-64
references.pmid: 18302714
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4572-83
references.pmid: 18628472
references.citation: Leukemia. 2006 Oct;20(10):1731-7
references.pmid: 17041637
references.citation: Stem Cells. 2001;19(5):443-52
references.pmid: 11553853
references.citation: BMC Cancer. 2006 Sep 26;6:229
references.pmid: 17002788
references.citation: Pediatr Blood Cancer. 2007 Dec;49(7):928-40
references.pmid: 17066459
references.citation: Klin Padiatr. 1997 Jul-Aug;209(4):178-85
references.pmid: 9293448
references.citation: Br J Haematol. 2007 May;137(4):319-28
references.pmid: 17456054